Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05421663 | A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma | PHASE1 | RECRUITING | 439 | — | — | Aug 12, 2022 | Jul 30, 2041 | Jun 5, 2026 | 32 | United States, Australia +6 |
Occurrence of any AEs, including dose limiting toxicities (DLTs).
Overall response is defined as a PR or CR at any point between the time of prizlo-cel infusion until PD or start of subsequent anti-lymphoma therapy, whichever occurs first (per Lugano 2014 guidelines).
| Arm | Type | Description |
|---|---|---|
| Prizlo-Cel | EXPERIMENTAL | Participants will receive intravenous (IV) infusion of autologous prizlo-cel. |
| Name | Type | Description |
|---|---|---|
| Prizloncabtagene autoleucel (Prizlo-Cel) | BIOLOGICAL | Prizlo-Cel, an autologous dual targeting chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)20 and CD19. |
Inclusion Criteria: * Participant must be greater than or equal to (\>=) 18 years of age, at the time of signing informed consent * Tumor must be histologically confirmed cluster of differentiation (CD)19 and/or CD20 positive * Must meet the indications for each subtype in Phase 1b as specified in ...